Minnesota Oncology Hematology

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 1/21 trial
• Phase 21 trial
• Phase 2/31 trial
• Phase 31 trial

Status

• Recruiting3 trials
• Active, not recruiting1 trial

Lead sponsor

• Bristol-Myers Squibb2 trials
• Artios Pharma Ltd1 trial
• SCRI Development Innovations, LLC1 trial

Running trials

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

  Contact: Daniel Mundt, Site 0322

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Eric Lander, Site 0313

• Active, not recruiting

  BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

  NCT06773910· Phase 2· SCRI Development Innovations, LLC· Source

• Recruiting

  A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  NCT04657068· Phase 1/2· Artios Pharma Ltd· Source

  Contact: Sarah Cannon Development Innovations

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting